FindTrial
Sign In

Evaluation of mitral valve morphology in patients with functional or degenerative mitral regurgitation using echocardiography

Evaluation of mitral valve morphology in patients with functional or degenerative mitral regurgitation using echocardiography

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029701
Enrollment
Unknown
Registered
2020-02-09
Start date
2020-02-10
Completion date
Unknown
Last updated
2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mitral Valve Disease

Interventions

Functional mitral regurgitation associated with atrial fibrillation requires transesophageal echocardiography (group 1):None.
Eighty Patients with degenerative mitral regurgitation need transesophageal echocardiography (group 2):None
Because of patent foramen ovale or fever to undertake transesophageal echocardiography and confirmed that no other abnormal cardiac anamoly was found (group 3):None
Functional mitral regurgitation secondary to ventricular septal defect or patent ductus arteriosus (group 4):None
healthy volunteers (group 5):None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
No minimum to 90 Years

Inclusion criteria

Inclusion criteria: 1. Functional mitral regurgitation associated with atrial fibrillation requires transesophageal echocardiography, 270 patients (group 1); 2. Eighty Patients with degenerative mitral regurgitation need transesophageal echocardiography (group 2); 3. Because of patent foramen ovale or fever to undertake transesophageal echocardiography and confirmed that no other abnormal cardiac anamoly was found, 50 patients (group 3); 4. Functional mitral regurgitation secondary to ventricular septal defect or patent ductus arteriosus, aged 0 to 8 years old, transthoracic echocardiography were performed in 100 cases (group 4); 5. 0 to 8 years old healthy volunteers, a total of 50 cases (group 5).

Exclusion criteria

Exclusion criteria: 1. Group 1: Patients with severe pulmonary, liver or kidney disease or malignant tumor, patients with primary valve disease, patients with hyperthyroidism, and patients with pregnancy. 2. Group 2: Patients with severe pulmonary, liver or kidney disease or malignant tumor, and patients with other structural pericardium besides valvular disease; 3. Group 3: Ppatients with severe pulmonary, liver or kidney disease or malignant tumor, and patients with other structural cardiovascular disease except valvular disease; 4. Group 4: Combined with other cardiac malformations; 5. Group 5: Used to undertake heart surgery.

Design outcomes

Primary

MeasureTime frame
Mitral regurgitation volume;Diameter of Mitral Annulus;Circumference of Mitral Annulus;Area of Mitral Valve;Coaptation Index;Non-planar Angle;Aorto-Mitral Angle;Mitral Valve Tenting Volume;Mitral Valve Tenting Height;Mitral Prolapse Height;Commissural Diameter;Annulus Area;Anterior Leaflet Area;Posterior Leaflet Area;Anterior Leaflet Length;Posterior Leaflet Length;Posterior Leaflet Angle;Sphericity index (AP / AL-PM);Annulus Area Fraction (2D);Left Ventricular Ejection Fraction;Left ventricular end-diastolic diameter;Left ventricular diameter;global longitudinal strain;global circumference strain;Global longitudinal displacement;Twist;Torsion;Time to Peak;Synchronization index;—

Countries

China

Contacts

Public ContactBai Wenjuan

West China Hospital, Sichuan University

littlewhitehx@126.com+86 18980860406

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026